ONTRANS: Oral Nicotinamide for skin cancer chemoprevention after Transplant

ONTRANS：口服烟酰胺用于移植后皮肤癌的化学预防

• 批准号: nhmrc : 1108328
• 负责人: A/Pr Pablo Fernandez Peñas
• 金额: $ 42.98万
• 依托单位: Australian National University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/ontrans-oral-nicotinamide-chemoprevention-transplant/663039
• 关键词: ONTRANS; Oral; Nicotinamide; skin; cancer

The skin’s immune system is a key defence against skin cancer. Transplant recipients, who are chronically and profoundly immune suppressed to prevent rejection, have a 50-80 fold increase in skin cancer risk. Nicotinamide (vitamin B3) reduced skin cancer in our recent Phase 3 trial in immune competent individuals. A pilot study in renal transplant patients showed similar results. This project will determine at the Phase 3 level whether nicotinamide reduces skin cancers after kidney transplant.

皮肤的免疫系统是抵御皮肤癌的关键防御系统。移植受者长期受到免疫抑制，以防止排斥反应，皮肤癌风险增加50-80倍。在我们最近对免疫能力良好的个人进行的第三阶段试验中，烟酰胺(维生素B3)减少了皮肤癌。在肾移植患者中进行的一项试点研究也显示了类似的结果。该项目将在第三阶段确定烟酰胺是否能减少肾移植后的皮肤癌。